黄奇改善了通过调节NF-κB信号通路的肠道屏障功能障碍在慢过渡便秘模型小鼠中
Hua-Xian Chen1, Guo-Zhong Xiao1, Chao-Xin Yang1
1Department of General Surgery (Department of Coloproctology), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, Guangdong Province, China.
World journal of gastrointestinal surgery
|June 12, 2025
概括
黄奇 (HQD) 通过减少肠道屏障损伤,改善缓慢过渡性便秘 (STC). 它通过降低核因子-κB (NF-κB) 途径的调节和恢复肠道屏障功能来起作用.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 缓慢过渡性便秘 (STC) 与肠道屏障功能障碍有关.
- 黄奇 (HQD) 显示了STC的治疗潜力,但其潜在的机制需要阐明.
研究的目的:
- 为了确定HQD是否通过抑制核因子-κB (NF-κB) 信号通路来减轻STC.
- 调查HQD在STC中恢复肠道屏障完整性的作用.
主要方法:
- 在对照,STC模型和HQD治疗小鼠的结肠组织上利用单细胞RNA测序和空间转录组测序.
- 通过免疫组织化学评估了克劳丁-1,素2和NF-κB P65的蛋白质表达.
- 使用LS174T细胞系进行了体外研究,以评估HQD的影响.
主要成果:
- 在STC小鼠中,HQD治疗增强了肠道运动性,并恢复了粘膜表皮.
- STC的特征是减少了杯状细胞,减少了素2,激活了亡,并抑制了Wnt/β-catenin信号传递.
- HQD降低了表皮细胞中异常NF-κB通路的激活,促进了增殖和屏障修复.
结论:
- STC与显著的肠粘膜屏障损伤有关.
- 通过抑制表皮细胞中NF-κB信号传递,HQD显示出在治疗STC方面的潜力.
- 在STC中,HQD有助于恢复肠上皮细胞功能,并促进粘膜屏障的修复.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
145
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
145
01:17Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153